"Pfizer biotechnology"

#6274272

14 December 2020

Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amsterdam, the Netherlands on December 14, 2020

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6274274

14 December 2020

Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amsterdam, the Netherlands on December 14, 2020

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6274276

14 December 2020

Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amsterdam, the Netherlands on December 14, 2020

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6274278

14 December 2020

Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amsterdam, the Netherlands on December 14, 2020

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6227294

29 November 2020

A medical syringe and a vial in front of the Pfizer US pharmaceutical corporation and Biontech German biotechnology company logos are seen in this creative illustrative photo. More than one hundred fifty COVID-19 coronavirus vaccine are in development across the world, several of which have the third phase of clinical trials, as media reported. (Photo illustration by STR/NurPhoto)

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6227298

29 November 2020

A medical syringe and a vial in front of the Pfizer US pharmaceutical corporation and Biontech German biotechnology company logos are seen in this creative illustrative photo. More than one hundred fifty COVID-19 coronavirus vaccines are in development across the world, several of which have the third phase of clinical trials, as media reported. (Photo illustration by STR/NurPhoto)

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6227302

29 November 2020

A medical syringe and a vial in front of the Pfizer US pharmaceutical corporation and Biontech German biotechnology company logos are seen in this creative illustrative photo. More than one hundred fifty COVID-19 coronavirus vaccine are in development across the world, several of which have the third phase of clinical trials, as media reported. (Photo illustration by STR/NurPhoto)

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6198018

19 November 2020

A medical syringe in front of the Pfizer US pharmaceutical corporation and Biontech German biotechnology company logos is seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6198014

19 November 2020

A medical syringe and vials in front of the Pfizer US pharmaceutical corporation and Biontech German biotechnology company logos are seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6198020

19 November 2020

A medical syringe and vials in front of the Pfizer US pharmaceutical corporation and Biontech German biotechnology company logos are seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6198022

19 November 2020

A medical syringe and a vial in front of the Pfizer US pharmaceutical corporation and Biontech German biotechnology company logos are seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6198016

19 November 2020

A medical syringe and vials in front of the Pfizer US pharmaceutical corporation and Biontech German biotechnology company logos are seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6198024

19 November 2020

A medical syringe and vials in front of the Biontech German biotechnology company logo are seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6198026

19 November 2020

A medical syringe in front of the Biontech German biotechnology company logo is seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6198028

19 November 2020

A medical syringe and a vial in front of the Biontech German biotechnology company logo are seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6198030

19 November 2020

A medical syringe and a vial in front of the Biontech German biotechnology company logo are seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.